219 related articles for article (PubMed ID: 15577115)
1. [Vitamin D therapy in predialysis renal failure].
Ando R
Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
[TBL] [Abstract][Full Text] [Related]
2. [Serum calcium concentration and the safety of vitamin D therapy].
Ikeda Y; Takemoto F
Clin Calcium; 2004 Sep; 14(9):79-82. PubMed ID: 15577116
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
4. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
6. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
[TBL] [Abstract][Full Text] [Related]
7. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
8. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
Alghareeb A; Sabry A; Bawadekji H; Alsaran K
Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
[TBL] [Abstract][Full Text] [Related]
9. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
Okada N; Tsubakihara Y
Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
[TBL] [Abstract][Full Text] [Related]
10. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
11. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
[TBL] [Abstract][Full Text] [Related]
12. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
13. [Advantage of intravenous pulse therapy with calcitriol or maxacalcitol in dialysis patients with renal hyperparathyroidism].
Yumita S
Clin Calcium; 2004 Sep; 14(9):69-72. PubMed ID: 15577114
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
[TBL] [Abstract][Full Text] [Related]
15. Oral vitamin D3 pulse therapy for overt secondary hyperparathyroidism at pre-dialysis stage.
Watanabe Y; Inaguma D; Fukuzawa Y; Kumon S; Yamazaki C
Nephrol Dial Transplant; 1996 May; 11(5):910-1. PubMed ID: 8671931
[No Abstract] [Full Text] [Related]
16. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
19. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
20. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
Daisley-Kydd RE; Mason NA
Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]